Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03668613
Recruitment Status : Active, not recruiting
First Posted : September 12, 2018
Last Update Posted : July 15, 2019
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
This was an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic plaque psoriasis. 84 subjects (most with moderate severity) were enrolled. Subjects were stratified by weight.

Condition or disease Intervention/treatment Phase
Moderate to Severe Chronic Plaque-type Psoriasis Drug: secukinumab low dose Drug: secukinumab high dose Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 84 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open-label, Multicenter Trial to Assess the Efficacy of Subcutaneous Secukinumab after12 Weeks of Treatment, and to Assess the Long-term Safety, Tolerability, Efficacy in Subjects From 6 to <18 Years of Age With Moderate to Severe Chronic Plaque Psoriasis
Actual Study Start Date : August 29, 2018
Estimated Primary Completion Date : September 18, 2019
Estimated Study Completion Date : September 13, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis
Drug Information available for: Secukinumab

Arm Intervention/treatment
Experimental: secukinumab low dose
secukinumab low dose
Drug: secukinumab low dose
dose depends on the weight group

Experimental: secukinumab high dose
secukinumab high dose
Drug: secukinumab high dose
dose depends on the weight group




Primary Outcome Measures :
  1. Number of participants with PASI 75 response [ Time Frame: week 12 ]

    Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per the standard procedure

    PASI 75 represents the percentage (or number) of patients who have achieved a 75% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.


  2. Number of participants with IGA mod 2011 0 or 1 response [ Time Frame: week 12 ]
    Investigator will assess the disease using the validated Investigator Global Assessment (IGA) mod 2011 and rate the disease from a score of 0 (clear skin) to 4 (severe disease)


Secondary Outcome Measures :
  1. Number of particiopants with PASI 90 response [ Time Frame: week 12 ]

    Psoriasis Area and Severity Index (PASI) will be assessed/calculated as per the standard procedure

    PASI 90 represents the percentage (or number) of patients who have achieved a 90% or more reduction in their PASI score from baseline. PASI 100 indicates patients who have achieved a complete resolution of all disease.

    *Other clinical laboratory variables may be included in the results reporting


  2. Number of Participants with Adverse Events [ Time Frame: up to week 224 ]
    clinical safety and tolerability will be assessed by adverse event monitoring

  3. Secukinumab concentration in serum [ Time Frame: up to week 224 ]
    standard pharmacokinetic parameters will be evaluated



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written informed assent and parental permission (age as per local law) obtained at screening before any assessment is performed.
  2. Must be 6 to less than 18 years of age at the time of randomization
  3. Moderate to Severe plaque psoriasis, defined as a PASI score ≥ 12, and IGA mod 2011 score of ≥ 3, and BSA involvement of ≥10%, at randomization.
  4. Subject being regarded by the investigator to be a candidate for systemic therapy.

Exclusion Criteria:

  1. Forms of psoriasis other than chronic plaque-type active at randomization
  2. Drug-induced psoriasis
  3. Ongoing use of prohibited treatments
  4. Female subjects of childbearing potential defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing and for 16 weeks after stopping study treatment
  5. Pregnant or nursing (lactating) females
  6. Subjects with total WBC count <2,500/μL, or platelets <100,000/μL or neutrophils <1,500/μL or hemoglobin <8.5 g/dL at screening
  7. Previous exposure to secukinumab or any other biologic drug directly targeting IL-17 or the IL-17 receptor

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03668613


Locations
Layout table for location information
United States, California
Novartis Investigative Site
California City, California, United States, 92708
United States, Florida
Novartis Investigative Site
Jacksonville, Florida, United States, 32256
Novartis Investigative Site
Miami, Florida, United States, 33155
United States, New Hampshire
Novartis Investigative Site
Lebanon, New Hampshire, United States, 03756
United States, Texas
Novartis Investigative Site
San Antonio, Texas, United States, 78218
Belgium
Novartis Investigative Site
Bruxelles, Belgium, 1200
Novartis Investigative Site
Liege, Belgium, 4000
Czechia
Novartis Investigative Site
Hradec Kralove, CZE, Czechia, 500 05
Novartis Investigative Site
Prague, Prague 1, Czechia, 11000
Estonia
Novartis Investigative Site
Tartu, Estonia, 51014
Germany
Novartis Investigative Site
Dresden, Germany, 01307
Novartis Investigative Site
Muenster, Germany, 48149
Peru
Novartis Investigative Site
Lima, Peru, 1
Poland
Novartis Investigative Site
Warszawa, Mazowian, Poland, 02 495
Novartis Investigative Site
Rzeszow, Poland, 35 055
Novartis Investigative Site
Wroclaw, Poland, 50 566
Russian Federation
Novartis Investigative Site
Kazan, Russian Federation, 420012
Novartis Investigative Site
Krasnodar, Russian Federation, 350020
Novartis Investigative Site
Moscow, Russian Federation, 119296
Novartis Investigative Site
Saint Petersburg, Russian Federation, 191123
Spain
Novartis Investigative Site
Esplugues de Llobregat, Barcelona, Spain, 08950
Novartis Investigative Site
Sabadell, Barcelona, Spain, 08208
Novartis Investigative Site
Valencia, Comunidad Valenciana, Spain, 46026
Novartis Investigative Site
Madrid, Spain, 28041
Novartis Investigative Site
Madrid, Spain, 28046
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03668613    
Other Study ID Numbers: CAIN457A2311
2017-004515-39 ( EudraCT Number )
First Posted: September 12, 2018    Key Record Dates
Last Update Posted: July 15, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
pediatric
secukinumab
plaque psoriasis
AIN457A
Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs